Heart failure registries - Future directions.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8804703 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1876-4738 (Electronic) Linking ISSN: 09145087 NLM ISO Abbreviation: J Cardiol Subsets: MEDLINE
    • Publication Information:
      Publication: Amsterdam : Elsevier
      Original Publication: Tokyo : Japanese College Of Cardiology
    • Subject Terms:
      Heart Failure*/diagnosis ; Heart Failure*/therapy; Humans ; Treatment Outcome ; Hospitalization ; Registries ; Sweden ; Randomized Controlled Trials as Topic
    • Abstract:
      Heart failure (HF) is a growing, global public health issue. Despite advances in HF care, many challenges remain and HF outcomes are poor. Some of the major reasons for this are the lack of understanding and treatment for certain HF sub-types as well as the lack of implementation of treatment in areas where effective treatment exists. HF registries provide the opportunity to transform clinical research and patient care. Recently the registry-based randomized clinical trial has emerged as a pragmatic and inexpensive alternative to the gold standard in clinical trial design, the randomized controlled trial. Registries may also provide platforms for strategy trials, implementation trials, and screening. Using examples from the Swedish Heart Failure Registry and others, the present review provides insights into how registry-based research can address many of the unmet needs in HF.
      Competing Interests: Declaration of competing interest TP: None. PK: None related to the present work. Reports fee for lectures from Vifor and personal fee for lecture from AstraZeneca. LHL: None related to the present work. Outside the present work: Grants: AstraZeneca, Vifor, Boston Scientific, Boehringer Ingelheim, Novartis, MSD; Consulting: Vifor, AstraZeneca, Bayer, Pharmacosmos, MSD, MedScape, Sanofi, Lexicon, Myokardia, Boehringer Ingelheim, Servier, Edwards Life Sciences, Alleviant; Speaker's honoraria: Abbott, OrionPharma, MedScape, Radcliffe, AstraZeneca, Novartis, Boehringer Ingelheim, Bayer; Patent: AnaCardio.
      (Copyright © 2023 Elsevier Ltd. All rights reserved.)
    • Contributed Indexing:
      Keywords: Clinical registries; Heart failure; Implementation; RRCT
    • Publication Date:
      Date Created: 20231016 Date Completed: 20231218 Latest Revision: 20231218
    • Publication Date:
      20231218
    • Accession Number:
      10.1016/j.jjcc.2023.10.006
    • Accession Number:
      37844799